The clinical-grade PERK inhibitor (HC4) eradicated quiescent cancer cell micro-metastases in the bone marrow and lungs of HER2+ breast cancers in syngeneic and patient-derived xenograft models [207]. This evidence concerns the gene ERBB2 and breast carcinoma.